IDEAYA Biosciences 2024年第四季度GAAP每股亏损$(1.49),低于预期$(0.64),销售额$700万高于预期$467万

财报速递
13 Feb
IDEAYA Biosciences(NASDAQ:IDYA)报告季度每股亏损$(1.49),低于分析师一致预期的$(0.64),差距为132.81%。 相比去年同期每股亏损$(0.52),这是一个186.54%的下降。 公司报告季度销售额为$700万,高于分析师一致预期的$467万,超出50.00%。相比去年同期的$392万,销售额增长了78.43%。

以上内容来自Benzinga Earnings专栏,原文如下:

IDEAYA Biosciences (NASDAQ:IDYA) reported quarterly losses of $(1.49) per share which missed the analyst consensus estimate of $(0.64) by 132.81 percent. This is a 186.54 percent decrease over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $7.00 million which beat the analyst consensus estimate of $4.67 million by 50.00 percent. This is a 78.43 percent increase over sales of $3.92 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10